Skip to main content
      RT @RichardPAConway: Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment respon

      Richard Conway RichardPAConway

      3 years 10 months ago
      Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment response in SLE nephritis . CD163 AUC 0.83 vs 0.75 for UPCR @THKC1 @RheumNow #ACR22 Abstr#0536 https://t.co/YI3JC2uKcv https://t.co/jnkfbI0Z1M
      RT @Yuz6Yusof: Here is a quick recap on #ACR22 Abstr#0355 Effect of voclosporin in class V lupus nephritis #lupus https:

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      Here is a quick recap on #ACR22 Abstr#0355 Effect of voclosporin in class V lupus nephritis #lupus https://t.co/0cR8On5UWN via @YouTube @RheumNow https://t.co/E25so6X2fj
      Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.
      RT @RichardPAConway: Wilson et al. Sputum ACPA or RF assoc RA development in serum ACPA+ individuals. x4 more likely - 4

      Richard Conway RichardPAConway

      3 years 10 months ago
      Wilson et al. Sputum ACPA or RF assoc RA development in serum ACPA+ individuals. x4 more likely - 46% vs 12%. @RheumNow #ACR22 Abstr#0533 https://t.co/7kpeXWjeKI https://t.co/Sx41DOJAAX
      RT @Yuz6Yusof: Please do catch up on my interview with Dr Amit Saxena, New York on their work. #ACR22 Abstr#2081 Breakth

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      Please do catch up on my interview with Dr Amit Saxena, New York on their work. #ACR22 Abstr#2081 Breakthrough COVID infection in SLE during Omicron era https://t.co/4dINWSobxj via @YouTube @RheumNow https://t.co/hIHWGRcu5h
      RT @RichardPAConway: Riskedal et al. DNA methyllation based biomarker for sero- RA. Accurary 1.0 for sero+ RA and reacti

      Richard Conway RichardPAConway

      3 years 10 months ago
      Riskedal et al. DNA methyllation based biomarker for sero- RA. Accurary 1.0 for sero+ RA and reactive arthritis, 0.75 sero-RA, 0.5 PsA. Promising but not there yet. @RheumNow #ACR22 Abstr#0531 https://t.co/clLR0V33WJ https://t.co/7Hts9gtkW9
      RT @uptoTate: Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. A

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow https://t.co/FeYrdlwQsA
      RT @ericdeinmd: In-person meetings are tough. Virtual meetings are tough. But hybrid meetings are logistical nightmares

      Eric Dein ericdeinmd

      3 years 10 months ago
      In-person meetings are tough. Virtual meetings are tough. But hybrid meetings are logistical nightmares Would've liked better WiFi and a live poster hall, but a HUGE credit to @ACRheum on planning a great #ACR22 hybrid meeting. Really amazing job @RheumNow
      RT @synovialjoints: Getting to know the COVID-19 drugs:

      ◦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evush

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Getting to know the COVID-19 drugs: ◦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evusheld) ◦ Post-exposure treatments: Paxlovid (po), Molnupiravir (po), Sotrovimab (IV), Remdesivir (IV) Rachael Perritt, COVID-19, #ACR22 @RheumNow https://t.co/bCwxJ9YfIU
      Show us how you ACR! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet o

      Dr. John Cush RheumNow

      3 years 10 months ago
      Show us how you ACR! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/aAUyhmrLPW
      2023 RWCS Meeting
      The ability to prevent RA in individuals at risk is a holy grail in rheumatology. There is a long history dating back to the PROMPT trial of methotrexate and PRAIRIE trial of rituximab. Both otrials showed an effect, but it seemed more likely to be a delaying of RA than prevention or modulation. Framing it another way, there were better outcomes in pre-RA because we were actually treating RA as it emerged with a proven effective treatment. It is
      RT @JulianSegan: Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very

      Julian Segan JulianSegan

      3 years 10 months ago
      Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very high baseline use (>50%) in this insurance claims database. Residual pain and harm minimisation still areas of need. @RheumNow #ACR22 ABST0925 https://t.co/XGHu0fIMF0 https://t.co/PutNNQiKnY
      RT @synovialjoints: JAK and TYK-2 inhibitors and indications in SpA:

      ● Tofacitinib ➣ Pan JAKi (AS, PsA)
      ● Baricit

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      JAK and TYK-2 inhibitors and indications in SpA: ● Tofacitinib ➣ Pan JAKi (AS, PsA) ● Baricitinib ➣ JAK1,2 ● Upadacitinib ➣ JAK1 (AxSpA, PsA) ● Deucravacitinib ➣ TYK2 (PsA) Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS
      ×